弥漫大B细胞淋巴瘤免疫化疗后无进展生存或无事件生存与总生存的相关性:一项系统综述
该系统综述纳入26项III期随机对照试验、4项II期试验和47项回顾性研究,评估初诊弥漫大B细胞淋巴瘤接受含利妥昔单抗化疗后无进展生存(PFS)和无事件生存(EFS)作为早期疗效终点的替代性。试验水平替代分析显示PFS(r=0.772)和EFS(r=0.838)与总生存(OS)相关,外部验证相关系数r为0.795-0.897。作者推荐PFS和EFS作为早期疗效终点。
要点
- 试验水平替代分析中PFS与OS相关(r=0.772,95%CI 0.471-0.913)。
- 试验水平替代分析中EFS与OS相关(r=0.838,95%CI 0.625-0.938)。
- 作者推荐PFS和EFS作为含利妥昔单抗免疫化疗患者的早期疗效终点。
核心结论
- 作者推荐PFS和EFS作为主要接受含利妥昔单抗免疫化疗的弥漫大B细胞淋巴瘤患者的早期疗效终点。
研究设计与样本
- 系统综述,纳入26项III期随机对照试验、4项II期试验和47项回顾性研究。
- 研究对象为初诊弥漫大B细胞淋巴瘤接受含利妥昔单抗化疗的患者,检索数据库截至2019年。
- 进行质量控制,排除高偏倚风险的研究;预测模型先在随机对照试验中建立,再在II期和回顾性人群中外部验证。
- 试验水平替代分析通过PFS或EFS的对数风险比与OS的对数风险比的相关性进行;治疗臂水平分析评估1、2、3和5年PFS或EFS率与5年OS的相关性。
- 相关性采用加权线性回归中的Pearson相关系数r评估,权重等于患者数量;敏感性分析采用逐一剔除亚组试验评估预测模型的一致性。
主要发现
- 试验水平替代分析中,PFS与OS相关(r=0.772;95%CI 0.471-0.913),EFS与OS相关(r=0.838;95%CI 0.625-0.938)。
- 在随机对照试验的利妥昔单抗免疫化疗治疗臂中,1至5年PFS率(r=0.813-0.873)或EFS率(r=0.853-0.931)与5年OS呈线性相关。
- 敏感性分析显示总体一致性合理。
- PFS与OS的相关性使用独立的II期和回顾性数据进行外部验证(r=0.795-0.897)。
临床怎么用
- 作者推荐PFS和EFS作为主要接受含利妥昔单抗免疫化疗的弥漫大B细胞淋巴瘤患者的早期疗效终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To investigate progression-free survival (PFS) and event-free survival (EFS) as early efficacy endpoints in diffuse large B-cell lymphoma (DLBCL), this systematic review included phase III randomized controlled trials (RCTs), phase II trials, and retrospective studies in newly diagnosed DLBCL receiving rituximab-containing chemotherapy through databases search up to 2019. Quality control was performed, where studies with high risk of bias were excluded. Prediction models were first established using the RCTs, and then externally validated in the phase II and retrospective populations. Trial-level surrogacy analysis was conducted by correlating the logarithmic (log) hazard ratio (HR) for PFS or EFS and log HR for OS. Correlation analysis at treatment arm-level was performed between 1-, 2-, 3-, and 5-year PFS or EFS rates and 5-year OS. The correlation was evaluated using the Pearson correlation coefficient r in weighted linear regression, with weight equal to patient size. Sensitivity analyses were performed to assess the consistency of predictive model by leaving one subgroup of trials out at a time. Twenty-six phase III RCTs, 4 phase II trials and 47 retrospective studies were included. In trial-level surrogacy, PFS (r, 0.772; 95% confidence interval [CI], 0.471-0.913) or EFS (r, 0.838; 95% CI, 0.625-0.938) were associated with OS. For rituximab immunochemotherapy treatment arms in RCTs, there was a linear correlation between 1 and 5-year PFS (r, 0.813-0.873) or EFS (r, 0.853-0.931) and 5-year OS. Sensitivity analysis demonstrated reasonable overall consistency. The correlation between PFS and OS was externally validated using independent phase II, and retrospective data (r, 0.795-0.897). We recommend PFS and EFS as earlier efficacy endpoints in patients with DLBCL primarily treated with rituximab-containing immunochemotherapy.
引用
- Zhu J, Yang Y, Tao J, et al. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia. 2020. PMID: 32651542. doi:10.1038/s41375-020-0963-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。